Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability ce...
Similar Items
-
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
by: Davide Bedognetti, et al.
Published: (2019-05-01) -
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
by: Davide Bedognetti, et al.
Published: (2019-07-01) -
Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force
by: Balwit James M, et al.
Published: (2010-12-01) -
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art
by: Lisa H. Butterfield, et al.
Published: (2018-12-01) -
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
by: James L Gulley, et al.
Published: (2023-03-01)